NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
NuCana plc reported a substantially narrower net loss for the second quarter of 2026, while continuing to advance its clinical development programs and maintain a cash runway expected to support operations into 2029. The Edinburgh-based clinical-stage biopharmaceutical company is focused on developing cancer medicines using its proprietary ProTide technology.
For the quarter ended June 30, 2026, NuCana reported a net loss of £3.1 million, compared with a net loss of £24.1 million in the same period of 2025. The significant year-over-year improvement was primarily associated with lower research and development and administrative expenses, as well as the absence of the large non-cash warrant revaluation expense recorded in the prior-year period.
The latest results come as NuCana continues to focus on its lead clinical candidate, NUC-7738, and its second development program, NUC-3373. The company said key clinical milestones remain on track, keeping investor attention focused on upcoming data and regulatory discussions rather than near-term revenue.
NuCana Q2 2026 Financial Results
NuCana’s second-quarter financial performance showed a marked improvement from the unusually large loss reported in Q2 2025. The company remains pre-revenue and has not yet generated product sales, meaning its financial results continue to be driven primarily by research, development, administrative costs and financing-related items.
The £3.1 million net loss for Q2 2026 compares with £24.1 million a year earlier. The 2025 result was heavily affected by a £12.6 million non-cash finance expense related to the revaluation of warrants issued as part of the company’s May 2025 financing.
That finance expense was absent in the latest quarter. As a result, the comparison between the two periods is particularly important because the improvement does not represent a sudden transition to profitability. Instead, it largely reflects lower operating expenses and the absence of an exceptional non-cash charge.
Research and Development Costs Decline
Research and development expenses were £2.3 million in the second quarter of 2026, down from £7.1 million in Q2 2025. The reduction was influenced by lower share-based payment expenses, although clinical development costs continued as NuCana advanced its lead programs.
For the first six months of 2026, research and development expenses totaled £5.5 million, compared with £8.8 million during the first half of 2025. NuCana said the reduction was primarily related to lower share-based payment expenses, partly offset by increased clinical trial costs.
NUC-7738 remained the largest research focus during the first half, accounting for approximately £4.3 million of development expenditure. Spending on NUC-3373 was approximately £0.7 million during the same period.
Administrative Expenses Also Fall
Administrative expenses were approximately £1.2 million in Q2 2026, compared with £4.5 million in the corresponding quarter of 2025. Lower share-based compensation and reduced professional fees contributed to the decline.
For the first six months, administrative expenses were £2.8 million, compared with £5.6 million in the prior-year period. The company said professional fees associated with the issuance of warrants in 2025 were not repeated in the latest period.
First-Half Loss Drops Sharply
The improvement was also visible across the first half of the year. NuCana reported a net loss of £6.9 million for the six months ended June 30, 2026, compared with £26.6 million for the first half of 2025.
Operating loss narrowed to approximately £8.0 million from £14.7 million. Finance income increased modestly, while the £12.6 million finance expense recorded during the first half of 2025 was absent in 2026.
The company therefore enters the second half of the year with a significantly cleaner income statement, although investors should continue to view NuCana as a development-stage biotechnology company whose future value depends heavily on clinical and regulatory progress.
Cash Position and Funding Outlook
NuCana had £19.5 million in cash and cash equivalents as of June 30, 2026, compared with £24.3 million at December 31, 2025. Despite the decline in cash during the first half, management expects existing resources to fund planned operations into 2029.
Net cash used in operating activities during the first six months was £5.2 million, compared with £7.6 million during the same period of 2025. The reduction in operating cash consumption reflects the lower overall loss and changes in working capital.
NuCana remains dependent on capital markets and other potential financing sources because it does not have an approved commercial product or product-sales revenue. The company has an at-the-market financing arrangement that provides additional flexibility to raise capital when appropriate.
The expected cash runway into 2029 is significant because it gives the company additional time to pursue clinical milestones without necessarily requiring immediate large-scale financing. However, future capital requirements could change depending on clinical development plans, regulatory requirements and the pace of expansion into additional indications.
NUC-7738 Remains the Key Clinical Program
The most important development program for NuCana is NUC-7738, a novel anti-cancer medicine being evaluated in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma.
NUC-7738 is designed to disrupt RNA polyadenylation and influence gene expression in cancer cells while also targeting aspects of the tumor microenvironment. The company believes the mechanism could provide potential advantages in cancers where resistance to existing treatments has developed.
NuCana previously reported clinical activity and a favorable safety profile from the program. The company is now moving toward final data from its Phase 2 expansion study, known as NuTide:701.
Melanoma Study Enrollment Completed
A key milestone during 2026 is the completion of patient recruitment for the Phase 2 expansion study evaluating NUC-7738 with pembrolizumab in PD-1 inhibitor-resistant melanoma.
With enrollment completed, investor focus shifts toward the final clinical readout. NuCana continues to expect final data from the study during 2026, making the upcoming results one of the most important potential catalysts for the company.
The company also received clearance from the U.S. Food and Drug Administration for an Investigational New Drug application for NUC-7738 earlier in 2026. This enables clinical investigation of the candidate in the United States, with melanoma expected to be an initial focus.
Regulatory Discussions Could Shape the Next Stage
Another important milestone is regulatory guidance from the FDA regarding a potential registrational strategy for NUC-7738 in melanoma.
For a clinical-stage biotechnology company, positive clinical data alone are not enough to establish commercial potential. The regulatory pathway, trial design and required evidence will determine how efficiently a promising treatment can move toward a potential approval application.
NuCana therefore expects its discussions with the FDA to help determine the most appropriate development strategy. The outcome could provide investors with greater clarity regarding the size, design and timing of future studies.
NUC-3373 Development Continues
NuCana’s second major development program is NUC-3373, a targeted thymidylate synthase inhibitor derived from the nucleoside analog 5-fluorouracil.
The company has previously evaluated NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors and in combination with docetaxel in lung cancer. During 2026, NuCana has been evaluating the optimal combinations and indications for potential future clinical studies.
While NUC-3373 is not currently receiving the same level of investor attention as NUC-7738, continued evaluation provides NuCana with another potential development pathway and could broaden the company’s pipeline if future studies produce supportive results.
What Investors Should Watch Next
The second half of 2026 could be an important period for NuCana. The most closely watched event is expected to be the final Phase 2 data from the NUC-7738 melanoma expansion study.
Investors will also be watching for regulatory feedback from the FDA, further development of U.S. clinical activities and progress toward evaluating additional indications and combination strategies.
Financially, maintaining the expected cash runway will remain important. Although the company ended June with £19.5 million in cash, continued clinical development requires ongoing spending. Any acceleration of development plans could alter the company’s cash requirements.
NuCana Outlook
NuCana’s Q2 2026 results present a more favorable financial picture than the same period last year, but the company’s investment case remains primarily clinical rather than financial.
The sharp reduction in the quarterly loss demonstrates better cost control and the absence of the large warrant-related accounting charge that affected 2025. At the same time, the company remains loss-making and has no commercial product revenue.
The central question for investors is therefore whether NUC-7738 can convert its earlier clinical signals into compelling final Phase 2 results and a credible regulatory development pathway. Completion of enrollment and the planned final data release represent important steps in that process.
With its cash resources expected to support operations into 2029, NuCana has additional time to execute its strategy. The company’s progress will ultimately depend on clinical outcomes, regulatory feedback, financing conditions and its ability to advance its pipeline efficiently.
Frequently Asked Questions
What was NuCana’s Q2 2026 net loss?
NuCana reported a net loss of approximately £3.1 million for the second quarter of 2026, compared with a £24.1 million loss in Q2 2025.
Why did NuCana’s loss narrow?
The improvement was mainly driven by lower research and development and administrative expenses and the absence of the £12.6 million non-cash warrant revaluation expense recorded in the second quarter of 2025.
How much cash did NuCana have at the end of Q2 2026?
NuCana reported approximately £19.5 million in cash and cash equivalents as of June 30, 2026. The company expects its existing resources to support planned operations into 2029.
What is NuCana’s lead drug candidate?
NUC-7738 is NuCana’s leading clinical program. It is being developed for cancer treatment, including evaluation in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma.
What is the next major milestone for NUC-7738?
The company expects final data from the Phase 2 NuTide:701 expansion study during 2026. Regulatory discussions with the FDA regarding a potential registrational strategy are another important milestone.
Is NuCana profitable?
No. NuCana remains a clinical-stage biotechnology company without approved commercial products or product-sales revenue. It is expected to continue reporting losses as it funds research and clinical development.
What should investors watch in the second half of 2026?
Key areas to monitor include final NUC-7738 clinical data, FDA regulatory guidance, additional development of NUC-7738 in new indications and combinations, progress on NUC-3373, and the company’s cash position.
Conclusion
NuCana’s second-quarter 2026 results show a substantial reduction in losses and lower operating expenses, while the company continues to advance its oncology pipeline. The financial improvement is encouraging, but the more important issue remains clinical execution.
With NUC-7738 moving toward final Phase 2 data in melanoma and regulatory discussions ahead, NuCana enters the remainder of 2026 with several potentially meaningful milestones. The company’s ability to demonstrate durable clinical benefit and establish a credible path toward later-stage development will remain the primary factor shaping its outlook.
